Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function.

PloS one - 1 Jan 2015

Heine Annkristin, Held Stefanie Andrea Erika, Daecke Solveig Nora, Riethausen Kati, Kotthoff Philipp, Flores Chrystel, Kurts Christian, Brossart Peter

Abstract excerpt

Inhibitors of VEGF receptor (VEGFR) signaling such as sorafenib and sunitinib that are currently used in the treatment of malignant diseases have been shown to affect immunological responses by inhibition of the function of antigen presenting cells and T lymphocytes. The VEGFR-inhibitor axitinib has recently been approved for second line therapy of metastatic renal cell carcinoma. While there is some evidence...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indazoles

Share to Kidney Neoplasms

Share to p38 Mitogen-Activated Protein Kinases

Share to Proto-Oncogene Proteins c-rel

Share to STAT3 Transcription Factor

Share to Vascular Endothelial Growth Factor A

Source

Open in PubMed Open full text

Identifiers

PMID: 26042424
DOI: 10.1371/journal.pone.0128897
PMCID: PMC4456373

Genes

STAT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function.PMID 26042424Read ↗

TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin PathwaySemantic proximity Read ↗

Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cellsSemantic proximity Read ↗

Activated apoptotic cells induce dendritic cell maturation via engagement of Toll-like receptor 4 (TLR4), dendritic cell-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin (DC-SIGN), and β2 integrins.Semantic proximity Read ↗

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivoSemantic proximity Read ↗

The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells.Semantic proximity Read ↗

Liver X receptors regulate dendritic cell phenotype and function through blocked induction of the actin-bundling protein fascin.Semantic proximity Read ↗

CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic TargetingSemantic proximity Read ↗

The CSF-1R inhibitor Pexidartinib impacts dendritic cell differentiation through inhibition of FLT3 signaling and may antagonize the effect of durvalumab in patients with advanced cancer – results from a phase 1 studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.